Brief: Delcath Systems Inc Expects To Submit NDA To FDA During Q1 2023 For Hepzato Kit
Jan 10 (Reuters) - Delcath Systems Inc DCTH.O :
* DELCATH SYSTEMS INC - NOW EXPECTS TO SUBMIT NDA TO U.S.
FDA
DURING Q1 2023 FOR ITS HEPZATO KIT
Source: (shorturl.at/lFLNX)
Further company coverage: DCTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Highlights Clinical Program Presentations At Esmo Congress 2026 And Independent Data On Percutaneous Hepatic Perfusion In Liver-Dominant Metastatic Uveal Melanoma
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Q2 revenue rises, beats estimates
Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview